Introduction {#s1}
============

Urogenital carcinomas, mainly including renal cell carcinoma (RCC), bladder carcinoma (BCa), and prostate carcinoma (PCa), are common malignancies among human neoplasms, with increasing morbidity worldwide in the last 2 decades (Dy et al., [@B15]). Based on the latest statistics in 2017, estimated incident of urogenital carcinomas accounts for about 20% of all tumors in the United States. Among them, PCa ranks the highest in man with 161,360 estimated new cases in 2017 (Siegel et al., [@B65]). In addition to life style and occupational exposure, numerous studies indicated genetic factors such as single nucleotide polymorphisms (SNPs) may be associated with urogenital carcinomas susceptibility (Sun et al., [@B67]; Stadler et al., [@B66]).

Angiogenesis, which is the process of new blood vessels formation from original pre-existing vessels, plays a critical role in tumor initiation and development (Nicholson and Theodorescu, [@B47]). The vascular endothelial growth factor (VEGF) gene is highly polymorphic and several functional SNPs in the VEGF gene alter the expression of the VEGF protein, thereby affecting tumor growth and progression (Ruggiero et al., [@B56]). The hypoxia-inducible factor-1 alpha (HIF1α) gene is an important transcription factor in cells which regulates cellular responses, adaption, and survival under low oxygen condition in physiological and pathological processes (Li et al., [@B33]). Several studies demonstrated HIF1α-rs11549465 polymorphism contributed to increase the risk of prostate cancer (Orr-Urtreger et al., [@B50]; Foley et al., [@B17]). Endothelial nitric oxide synthase (eNOS) is a central mediator of several endothelium growth stimulators, such as VEGF (Duda et al., [@B14]; Zhao et al., [@B77]). Polymorphisms of the eNOS gene plays a vital role in the angiogenesis pathway and have also been found to have functional and clinical significance in malignancies (Haque et al., [@B22]). HRAS (Harvey rat sarcoma viral oncogene homolog) gene has been uncovered as one of the major factors in the initiation and progression of human malignancies (Zhang et al., [@B76]). HRAS SNP was also noted to be associated with many cancer susceptibilities.

Clarifying of the role of VEGF/hypoxia/angiogenesis gene polymorphisms in the influence of cancer may improve our knowledge of tumor angiogenesis and benefit risk stratification, disease detection, and prognosis prediction. As mentioned above, many studies have conducted investigations to clarify the associations between these polymorphisms and the risk of urogenital carcinomas, however, these results are controversial and inconsistent. In the current study, we retrieved published data and performed a comprehensive meta-analysis to systematically investigate the association between polymorphisms in VEGF/hypoxia/angiogenesis pathway genes and the risk of urogenital carcinomas.

Materials and methods {#s2}
=====================

Acquisition of the VEGF/hypoxia/ angiogenesis pathway gene set
--------------------------------------------------------------

The gene set of VEGF/hypoxia/angiogenesis pathway was referenced from the Kyoto Encyclopedia of Genes and Genomes (KEGG) website. The VEGF/hypoxia/angiogenesis pathway gene set could be extracted via following URL link (<http://software.broadinstitute.org/gsea/msigdb/geneset_page.jsp?geneSetName=BIOCARTA_VEGF_PATHWAY&keywords=angiogenesis>). The gene set was originally provided via the KEGG signaling database, and encompassed the following 29 genes: ARNT, EIF1, EIF1AX, EIF2B1, EIF2B2, EIF2B3, EIF2B4, EIF2B5, EIF2S1, EIF2S2, EIF2S3, ELAVL1, FLT1, FLT4, HIF1A, HRAS, KDR, eNOS, PIK3CA, PIK3CG, PIK3R1, PLCG1, PRKCA, PRKCB, PTK2, PXN, SHC1, VEGF, and VHL.

Literature search strategy
--------------------------

We performed a literature search from PubMed, Web of Science, EMBASE, and Cochrane Central Search Library according to the PRISMA guidelines (Shamseer et al., [@B63]) (last research update: July 20, 2017). The search terms were as follows: (gene OR synset) AND (polymorphism OR mutation OR variation OR SNP OR genotype) AND (carcinoma OR cancer OR neoplasm OR adenocarcinoma OR tumor OR malignancy) (Supplementary Table [1](#SM3){ref-type="supplementary-material"}). The language of enrolled studies was restricted to English. Also, we identified additional articles by screening the references of enrolled articles and reviews.

Inclusion and exclusion criteria
--------------------------------

Studies fitting the following inclusion criteria were enrolled: (1) articles has shown the association between polymorphisms in genes of VEGF/hypoxia/angiogenesis pathway and risk of urogenital carcinomas; (2) case-control studies; (3) publications with sufficient genotype data to assess odds ratios (ORs) and 95% confidence intervals (CIs). The exclusion criteria were as follows: (1) case-only studies without a control group, case reports, conference abstracts or reviews; (2) studies without raw data for the genotype; (3) studies with overlapping data.

Data extraction
---------------

Two authors (JBC and MZ) individually extracted eligible data from each publication based on the inclusion and exclusion criteria. If there is a discrepancy, we reached agreement after discussing with a third author (XBZ). Information collected as follows: first author name, publication year, ethnicity, genotyping methods, source of controls including population-based (PB) or hospital-based (HB), Hardy-Weinberg equilibrium (HWE), cancer type, number of cases, and controls in the VEGF/hypoxia/angiogenesis genotypes. The Newcastle-Ottawa Scale (NOS) was used for assessing the quality of studies. High-quality study required score 7 to 9, and a score less than 7 defined as a low-quality study (Supplementary Table [2](#SM4){ref-type="supplementary-material"}).

Linkage disequilibrium (LD) analysis across populations
-------------------------------------------------------

The 1,000 genomes Project database (<https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/>) was used to extract the LD data, which comprising the polymorphisms in VEGF, HIF-1α and eNOS evaluated in the present study. Briefly, populations enrolled in the project including JPT (Japanese in Tokyo, Japan), YRI (Yoruba in Ibadan, Nigeria), CEU (Utah residents with Northern and Western European ancestry from the CEPH collection), and CHB (Han Chinese in Beijing, China). The LD was assessed by *r*^2^ statistics in these populations using Haploview software.

Statistical analysis
--------------------

The association between polymorphisms in four VEGF/hypoxia/angiogenesis pathway genes and the urogenital carcinomas susceptibility were evaluated using summary ORs and the corresponding 95%CIs. We used allelic (B vs. A), recessive (BB vs. BA + AA), dominant (BA + BB vs. AA), homozygous (BB vs. AA), and heterozygous (BA vs. AA) models to analyze each variable (A indicate wild allele and B indicate mutated allele). Q-statistic as well as *I*^2^ were used to evaluate the heterogeneity within the studies (Higgins et al., [@B24]). Heterogeneity was considered significant when the *P*-value \< 0.1. If there was no heterogeneity found, a fixed effect model was applied. Otherwise, the random-effect model was used to calculate pooled ORs. The significance of overall ORs was determined by Z-test. Subgroup analyses were performed based on different ethnicity, cancer type, HWE, and the source of control. Sensitivity analysis was conducted to assess the results stability by omitting one study each time. Publication bias was analyzed by Begg\'s funnel plot and Egger\'s test (Begg and Mazumdar, [@B4]; Egger et al., [@B16]). All analyses were performed using STATA 12.0 statistical software (Stata Corpotation, College Station, TX, USA).

Results {#s3}
=======

Main characteristics of the eligible studies
--------------------------------------------

According to the inclusion and exclusion criteria, only 12 polymorphisms in four genes of VEGF/hypoxia/angiogenesis pathway were identified (VEGF-rs10434, VEGF-rs1570360, VEGF-rs2010963, VEGF-rs3025039, VEGF-rs699947, VEGF-rs833061, HIF1a-rs11549465, HIF1a-rs11549467, eNOS-rs1799983, eNOS-rs2070744, eNOS-Intron 4a/b VNTR, and HRAS-rs12628). Details of the enrolled studies were listed in Table [1](#T1){ref-type="table"} (Clifford et al., [@B10]; Abe et al., [@B1]; McCarron et al., [@B41]; Medeiros et al., [@B43]; Johne et al., [@B29]; Lin et al., [@B36]; Sanyal et al., [@B61]; Chau et al., [@B8]; Kim et al., [@B30]; Marangoni et al., [@B39]; Sfar et al., [@B62]; Fukuda et al., [@B19]; Garcia-Closas et al., [@B20]; Li et al., [@B34], [@B35]; Orr-Urtreger et al., [@B50]; Jacobs et al., [@B26]; Nadaoka et al., [@B45]; Onen et al., [@B48]; Foley et al., [@B17]; Lee et al., [@B31]; Morris et al., [@B44]; Ricketts et al., [@B55]; Bruyère et al., [@B6]; VanCleave et al., [@B69]; Ajaz et al., [@B2]; Ryk et al., [@B57]; Sanli et al., [@B60]; Amasyali et al., [@B3]; Henríquez-Hernández et al., [@B23]; Qin et al., [@B53], [@B54]; Traczyk et al., [@B68]; Brankovic et al., [@B5]; Ianni et al., [@B25]; Jaiswal et al., [@B28]; Martinez-Fierro et al., [@B40]; Pandith et al., [@B51]; Sáenz-López et al., [@B58]; Safarinejad et al., [@B59]; Verim et al., [@B70]; Wang et al., [@B72]; Ziaei et al., [@B79]; Fraga et al., [@B18]; Yang et al., [@B74]; Lu et al., [@B38]; Polat et al., [@B52]; Shen et al., [@B64]; Xian et al., [@B73]; Ceylan et al., [@B7]; Diler and Oden, [@B12]). The study selection processes were presented in Figure [1](#F1){ref-type="fig"}.

###### 

Detail characteristics of enrolled studies.

  **SNP**                 **References**                       **Ethnicity**   **Source of control**   **Cancer type**   **Case**   **Control**   **Y(HWE)**                      
  ----------------------- ------------------------------------ --------------- ----------------------- ----------------- ---------- ------------- ------------ ------ ----- ----- ---
  VEGF-rs10434            Abe et al., [@B1]                    Asian           HB                      RCC               113        31            1            109    33    3     Y
                          Shen et al., [@B64]                  Asian           HB                      RCC               152        170           39           166    164   30    Y
                          Lu et al., [@B38]                    Asian           HB                      RCC               172        191           49           365    375   85    Y
  VEGF-rs1570360          McCarron et al., [@B41]              Caucasian       PB                      PCa               114        109           15           120    109   34    Y
                          Sfar et al., [@B62]                  Caucasian       HB                      PCa               58         37            6            36     50    14    Y
                          Garcia-Closas et al., [@B20]         Caucasian       HB                      BCa               431        383           78           389    407   82    Y
                          Jacobs et al., [@B26]                Caucasian       PB                      PCa               557        489           126          210    194   54    Y
                          Ricketts et al., [@B55]              Caucasian       PB                      RCC               134        143           47           146    130   38    Y
                          Bruyère et al., [@B6]                Caucasian       PB                      RCC               27         17            5            94     83    25    Y
                          Yang et al., [@B74]                  Asian           HB                      BCa               224        187           69           213    162   45    Y
                          Xian et al., [@B73]                  Asian           HB                      RCC               115        112           39           232    220   80    N
  VEGF-rs2010963          Sfar et al., [@B62]                  Caucasian       HB                      PCa               29         57            15           44     46    10    Y
                          Garcia-Closas et al., [@B20]         Caucasian       HB                      BCa               388        395           98           387    396   93    Y
                          Bruyère et al., [@B6]                Caucasian       PB                      RCC               15         25            8            86     92    20    Y
                          Sáenz-López et al., [@B58]           Caucasian       PB                      RCC               101        93            20           129    118   32    Y
                          Qin et al., [@B54]                   Asian           HB                      RCC               287        391           146          410    429   144   Y
                          Shen et al., [@B64]                  Asian           HB                      RCC               121        170           69           134    163   63    Y
                          Lu et al., [@B38]                    Asian           HB                      RCC               139        194           79           299    377   148   Y
                          Xian et al., [@B73]                  Asian           HB                      RCC               30         132           104          49     256   227   Y
  VEGF-rs3025039          Abe et al., [@B1]                    Asian           HB                      RCC               97         41            7            90     52    3     Y
                          Sfar et al., [@B62]                  Caucasian       HB                      PCa               79         20            2            72     27    1     Y
                          Garcia-Closas et al., [@B20]         Caucasian       HB                      BCa               852        217           17           787    385   11    N
                          Bruyère et al., [@B6]                Caucasian       PB                      RCC               29         17            1            141    53    2     Y
                          Sáenz-López et al., [@B58]           Caucasian       PB                      RCC               156        57            2            200    73    7     Y
                          Wang et al., [@B72]                  Asian           HB                      BCa               293        153           24           539    275   36    Y
                          Yang et al., [@B74]                  Asian           HB                      BCa               307        149           24           284    121   15    Y
                          Shen et al., [@B64]                  Asian           HB                      RCC               224        81            55           240    73    46    N
                          Lu et al., [@B38]                    Asian           HB                      RCC               262        91            59           554    166   105   N
                          Xian et al., [@B73]                  Asian           HB                      RCC               70         127           69           196    236   100   Y
  VEGF-rs699947           Kim et al., [@B30]                   Asian           HB                      BCa               13         69            71           11     69    73    Y
                          Garcia-Closas et al., [@B20]         Caucasian       HB                      BCa               261        471           220          268    447   214   Y
                          VanCleave et al., [@B69]             Mixed           PB                      PCa               125        53            12           402    198   35    Y
                          Ajaz et al., [@B2]                   Asian           NA                      RCC               30         81            32           44     41    21    Y
                          Henríquez-Hernández et al., [@B23]   Caucasian       HB                      BCa               11         25            23           14     16    13    Y
                          Sáenz-López et al., [@B58]           Caucasian       PB                      RCC               54         114           48           77     142   53    Y
                          Ianni et al., [@B25]                 Caucasian       HB                      PCa               115        54            55           75     57    24    N
                          Jaiswal et al., [@B28]               Asian           HB                      BCa               67         116           17           106    112   32    Y
                          Martinez-Fierro et al., [@B40]       Caucasian       HB                      PCa               37         38            2            70     78    24    Y
                          Shen et al., [@B64]                  Asian           HB                      RCC               150        149           61           178    141   41    Y
                          Lu et al., [@B38]                    Asian           HB                      RCC               171        174           67           397    332   95    N
                          Xian et al., [@B73]                  Asian           HB                      RCC               99         119           48           243    225   64    Y
  VEGF-rs833061           Lin et al., [@B36]                   Asian           HB                      PCa               60         32            4            43     72    4     N
                          Fukuda et al., [@B19]                Asian           HB                      PCa               143        103           24           132    97    23    Y
                          Garcia-Closas et al., [@B20]         Caucasian       HB                      BCa               237        434           216          243    432   198   Y
                          Onen et al., [@B48]                  Mixed           PB                      PCa               33         89            11           50     94    13    N
                          Bruyère et al., [@B6]                Caucasian       PB                      RCC               19         29            1            47     109   46    Y
                          Sáenz-López et al., [@B58]           Caucasian       PB                      RCC               56         111           49           77     138   58    Y
                          Wang et al., [@B72]                  Asian           HB                      BCa               255        178           37           475    307   68    Y
                          Lu et al., [@B38]                    Asian           HB                      RCC               228        93            91           513    168   143   N
  HIF1α-rs11549465        Clifford et al., [@B10]              Caucasian       HB                      RCC               42         6             0.1          110    27    6     N
                          Chau et al., [@B8]                   Mixed           NA                      PCa               161        29            6            179    14    3     N
                          Orr-Urtreger et al., [@B50]          Caucasian       PB                      PCa               287        99            16           217    80    3     Y
                          Li et al., [@B34]                    Mixed           PB                      PCa               818        209           14           995    221   18    Y
                          Jacobs et al., [@B26]                Mixed           PB                      PCa               1156       252           12           1138   284   28    N
                          Nadaoka et al., [@B45]               Asian           HB                      BCa               197        21            1            419    42    0.1   Y
                          Foley et al., [@B17]                 Caucasian       PB                      PCa               65         30            0.1          175    13    0.1   Y
                          Morris et al., [@B44]                Caucasian       PB                      RCC               290        39            3            262    46    5     Y
                          Li et al., [@B35]                    Asian           HB                      PCa               612        48            2            659    57    0.1   Y
                          Qin et al., [@B53]                   Asian           HB                      RCC               572        46            2            578    43    2     Y
                          Fraga et al., [@B18]                 Caucasian       HB                      PCa               579        164           11           566    156   14    Y
  HIF1α-rs11549467        Clifford et al., [@B10]              Caucasian       HB                      RCC               47         1             0.1          140    4     0.1   Y
                          Chau et al., [@B8]                   Mixed           NA                      PCa               195        1             0.1          196    0.1   0.1   N
                          Orr-Urtreger et al., [@B50]          Caucasian       PB                      PCa               198        2             0.1          298    2     0.1   Y
                          Li et al., [@B34]                    Mixed           PB                      PCa               1053       13            0.1          1247   17    0.1   Y
                          Nadaoka et al., [@B45]               Asian           HB                      BCa               204        13            2            421    40    0.1   Y
                          Morris et al., [@B44]                Caucasian       PB                      RCC               313        10            2            294    15    0.1   Y
                          Li et al., [@B35]                    Asian           HB                      PCa               614        47            1            685    31    0.1   Y
                          Qin et al., [@B53]                   Asian           HB                      RCC               575        45            0.1          584    39    0.1   Y
  eNOS-rs1799983          Medeiros et al., [@B43]              Caucasian       HB                      PCa               49         61            15           70     65    18    Y
                          Marangoni et al., [@B39]             Caucasian       HB                      PCa               30         50            4            30     29    6     Y
                          Jacobs et al., [@B26]                Caucasian       PB                      PCa               659        632           129          682    600   164   Y
                          Lee et al., [@B31]                   Caucasian       PB                      PCa               517        468           103          607    557   129   Y
                          Lee et al., [@B31]                   Mixed           PB                      PCa               77         20            0.1          280    88    5     Y
                          Ryk et al., [@B57]                   Caucasian       PB                      BCa               128        106           28           75     62    13    Y
                          Ziaei et al., [@B79]                 Caucasian       HB                      PCa               44         23            11           48     33    6     Y
                          Safarinejad et al., [@B59]           Caucasian       HB                      PCa               120        48            2            248    89    3     Y
                          Verim et al., [@B70]                 Caucasian       HB                      BCa               7          49            10           31     44    13    Y
                          Brankovic et al., [@B5]              Caucasian       HB                      PCa               76         65            9            54     40    6     Y
                          Polat et al., [@B52]                 Caucasian       PB                      BCa               7          59            9            48     75    20    Y
                          Ceylan et al., [@B7]                 Caucasian       HB                      PCa               46         23            9            47     23    5     Y
                          Diler et al., 2016                   Caucasian       PB                      PCa               6          55            23           65     41    10    Y
  eNOS-rs2070744          Ryk et al., [@B57]                   Caucasian       PB                      BCa               152        142           40           84     63    8     Y
                          Safarinejad et al., [@B59]           Caucasian       HB                      PCa               52         93            25           150    159   31    Y
                          Brankovic et al., [@B5]              Caucasian       HB                      PCa               54         68            28           34     51    15    Y
                          Polat et al., [@B52]                 Caucasian       PB                      BCa               24         40            11           56     72    15    Y
                          Diler et al., 2016                   Caucasian       PB                      PCa               30         30            24           47     56    13    Y
  eNOS-Intron 4a/b VNTR   Medeiros et al., [@B43]              Caucasian       HB                      PCa               87         32            6            121    29    3     Y
                          Sanli et al., [@B60]                 Caucasian       HB                      PCa               87         40            5            104    48    6     Y
                          Amasyali et al., [@B3]               Caucasian       HB                      BCa               52         63            8            137    59    5     Y
                          Safarinejad et al., [@B59]           Caucasian       HB                      PCa               101        54            15           249    88    3     Y
                          Polat et al., [@B52]                 Caucasian       PB                      BCa               50         24            1            97     43    3     Y
                          Diler et al., 2016                   Caucasian       PB                      PCa               65         16            3            83     31    2     Y
  HRAS-rs12628            Johne et al., [@B29]                 Caucasian       HB                      BCa               151        119           42           164    170   26    N
                          Sanyal et al., [@B61]                Caucasian       PB                      BCa               153        147           2            54     61    6     N
                          Traczyk et al., [@B68]               Caucasian       PB                      BCa               45         64            23           49     48    9     Y
                          Pandith et al., [@B51]               Asian           HB                      BCa               90         42            8            135    25    0.1   Y

*SNP, single nucleotide polymorphism; HB, hospital-based; PB: population-based; RCC, renal cell carcinoma; PCa, prostate cancer; BCa, bladder cancer; HWE, Hardy Weinberg equilibrium; Y, controls conformed to HWE; N, controls were not conformed to HWE; Mixed, more than two ethnicities*.
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For polymorphisms in VEGF gene (VEGF-rs10434, VEGF-rs1570360, VEGF-rs2010963, VEGF-rs3025039, VEGF-rs699947, VEGF-rs833061), a total of 49 case-control studies with 8,070 cases and 10,024 controls have met the inclusion criteria. Specifically, there are 918 cases and 1,330 controls in VEGF-rs10434, 3,522 cases and 3,167 controls in VEGF-rs1570360, 3,106 cases and 4,152 controls in VEGF-rs2010963, 3,582 cases and 4,890 controls in VEGF-rs3025039, 3,252 cases and 4,432 controls in VEGF-rs699947, 2,533 cases and 3,550 controls in VEGF-rs833061, respectively. Twenty-two studies of them were performed in Caucasians, 25 studies in Asians, and others were in mixed ethnic groups (including at least one race). Controls of 35 studies were hospital-based (H-B) and 13 studies were population-based (P-B), only one study didn\'t show whether it was H-B or P-B. Additionally, the distributions of polymorphisms in VEGF for control groups were consistent with HWE, except for these studies listed here (Lin et al., [@B36]; Garcia-Closas et al., [@B20]; Onen et al., [@B48]; Ianni et al., [@B25]; Lu et al., [@B38]; Shen et al., [@B64]; Xian et al., [@B73]).

For HIF1α-rs11549465 and rs11549467 polymorphisms, 19 eligible studies comprising 6,064 cases and 6,784 controls were enrolled. There are 5789 cases and 6,360 controls in HIF1α-rs11549465, 3,336 cases and 4,013 controls in HIF1α-rs11549467, respectively. Of them, eight studies were performed on subjects in Caucasians, six in Asians and the other five were in mixed ethnic groups. Moreover, nine studies were H-B, eight were P-B and the other two did not show H-B or P-B. There were several studies not consistent with HWE (Clifford et al., [@B10]; Chau et al., [@B8]; Jacobs et al., [@B26]).

For polymorphisms in eNOS gene (eNOS-rs1799983, eNOS-rs2070744, and eNOS-Intron 4a/b VNTR), 24 case-control studies with 4,286 cases and 5,009 controls were included in the current work. Specifically, there are 3,777 cases and 4,429 controls in eNOS-rs1799983, 813 cases, and 854 controls in eNOS-rs2070744, 709 cases and 1,111 controls in eNOS-Intron 4a/b VNTR, respectively. Of them, 23 studies were performed in Caucasian, 1 was in mixed ethnic groups. In addition, among these studies, 13 were H-B, and 11 were P-B. All the studies were consistent with HWE. While for HRAS-rs12628 polymorphism, finally, 4 eligible case-control studies comprising 886 cases and 747 controls were included. Of them, 3 studies were performed in Caucasian, 1 in Asian. Of these studies, 2 were H-B, and 2 were P-B. Two studies were not consistent with HWE (Johne et al., [@B29]; Sanyal et al., [@B61]).

Quantitative synthesis
----------------------

Table [2](#T2){ref-type="table"} and Supplementary Table [3](#SM5){ref-type="supplementary-material"} listed the main results of current meta-analysis work of polymorphisms in VEGF/hypoxia/angiogenesis pathway genes and risk of urogenital carcinomas.

###### 

Representative results of meta-analysis for polymorphisms in VEGF/ Hypoxia/Angiogenesis genes and risk of Urogenital Carcinomas.

  **SNP**                 **Comparison**   **Subgroup**   **N**   ***P*~H~**   ***P*~A~**            **Random**               **Fixed**
  ----------------------- ---------------- -------------- ------- ------------ --------------------- ------------------------ ----------------------
  eNOS-rs2070744          B vs. A          Overall        5       0.471        **2.566E-05^\*\*^**   1.379 (1.188--1.602)     1.379 (1.187--1.602)
                          B vs. A          PB             3       0.746        **6.260E-04**         1.436 (1.167--1.768)     1.437 (1.167--1.768)
                          B vs. A          BCa            2       0.599        **7.782E-03^\*^**     1.387 (1.089--1.767)     1.388 (1.090--1.768)
                          B vs. A          PCa            3       0.196        **1.113E-03^\*^**     1.362 (1.060--1.751)     1.373 (1.135--1.662)
                          BA+BB vs. AA     BCa            2       0.922        **3.913E-02^\*^**     1.402 (1.017--1.932)     1.402 (1.017--1.932)
                          BA+BB vs. AA     PCa            3       0.125        **2.278E-02^\*^**     1.307 (0.865--1.974)     1.375 (1.045--1.808)
                          BB vs. AA        Overall        5       0.466        **1.814E-05^\*\*^**   2.082 (1.481--2.926)     2.097 (1.495--2.942)
                          BB vs. AA        PB             3       0.657        **2.220E-04^\*\*^**   2.453 (1.510--3.985)     2.481 (1.532--4.019)
                          BB vs. AA        BCa            2       0.438        **6.251E-03^\*^**     2.241 (1.225--4.099)     2.298 (1.266--4.172)
                          BB vs. AA        PCa            3       0.235        **9.759E-04^\*^**     2.001 (1.211--3.306)     2.000 (1.325--3.018)
                          BB vs. BA+AA     Overall        5       0.414        **5.468E-05^\*\*^**   1.876 (1.370--2.567)     1.898 (1.390--2.591)
                          BB vs. BA+AA     PB             3       0.393        **1.915E-04^\*\*^**   2.331 (1.481--3.668)     2.352 (1.501--3.687)
                          BB vs. BA+AA     BCa            2       0.358        **1.503E-02^\*^**     1.946 (1.099--3.446)     2.006 (1.145--3.516)
                          BB vs. BA+AA     PCa            3       0.214        **1.300E-03^\*^**     1.869 (1.166--2.997)     1.848 (1.271--2.687)
  eNOS-Intron 4a/b VNTR   BB vs. BA+AA     Overall        6       0.109        **1.970E-04^\*\*^**   2.436 (1.109--5.351)     2.725 (1.608--4.619)
                          BB vs. AA        BCa            2       0.150        **4.899E-02^\*^**     2.157 (0.367--12.659)    2.661 (1.004--7.050)
  eNOS-rs1799983          B vs. A          BCa            3       0.190        **1.078E-02^\*^**     1.361 (1.024--1.809)     1.324 (1.067--1.642)
                          BB vs. AA        BCa            3       0.229        **2.056E-02^\*^**     2.070 (1.049--4.085)     1.887 (1.103--3.230)
  HIF1α-rs11549467        B vs. A          PCa            4       0.490        **4.413E-02^\*^**     1.461 (1.003--2.128)     1.465 (1.010--2.124)
  HRAS-rs12628            BA+BB vs. AA     Y              2       0.127        **3.647E-05^\*\*^**   2.220 (1.245--3.960)     2.211 (1.517--3.222)
                          BB vs. AA        Y              2       0.163        **5.725E-04^\*\*^**   7.207 (0.158--328.963)   4.174 (1.851--9.412)
                          BB vs. BA+AA     HB             2       0.176        **5.642E-04^\*\*^**   4.887 (0.138--172.923)   2.396 (1.458--3.938)
  VEGF-rs2010963          BA vs. AA        RCC            6       0.530        **1.762E-02^\*^**     1.168 (1.027--1.327)     1.168 (1.027--1.328)
                          BA+BB vs. AA     RCC            6       0.240        **6.790E-03^\*^**     1.158 (0.996--1.346)     1.181 (1.047--1.333)
                          BB vs. AA        RCC            6       0.131        **3.784E-02^\*^**     1.156 (0.910--1.468)     1.196 (1.010--1.416)
  VEGF-rs3025039          B vs. A          Asian          6       0.337        **4.545E-04^\*\*^**   1.179 (1.067--1.303)     1.180 (1.076--1.294)
                          B vs. A          RCC            6       0.195        **1.199E-03^\*^**     1.183 (1.028--1.363)     1.198 (1.074--1.336)
                          BA+BB vs. AA     RCC            6       0.148        **9.705E-03^\*^**     1.194 (0.986--1.446)     1.205 (1.046--1.389)
                          BB vs. AA        Asian          6       0.548        **7.532E-04^\*\*^**   1.400 (1.149--1.705)     1.401 (1.152--1.705)
                          BB vs. AA        HB             8       0.773        **4.316E-04^\*\*^**   1.404 (1.160--1.698)     1.405 (1.163--1.699)
                          BB vs. AA        RCC            6       0.244        **3.699E-03^\*^**     1.394 (1.043--1.863)     1.383 (1.111--1.721)
                          BB vs. BA+AA     RCC            6       0.455        **1.930E-02^\*^**     1.286 (1.046--1.582)     1.278 (1.041--1.570)
  VEGF-rs699947           B vs. A          Asian          6       0.286        **9.201E-07^\*\*^**   1.273 (1.139--1.424)     1.277 (1.158--1.408)
                          B vs. A          RCC            5       0.603        **1.311E-07^\*\*^**   1.311 (1.186--1.451)     1.312 (1.186--1.450)
                          BA vs. AA        Asian          6       0.102        **6.730E-05^\*\*^**   1.395 (1.122--1.734)     1.352 (1.166--1.568)
                          BA vs. AA        RCC            5       0.109        **5.669E-04^\*\*^**   1.347 (1.081--1.678)     1.306 (1.122--1.521)
                          BA+BB vs. AA     Asian          6       0.221        **1.339E-06^\*\*^**   1.427 (1.198--1.700)     1.410 (1.226--1.620)
                          BA+BB vs. AA     RCC            5       0.189        **4.602E-06^\*\*^**   1.417 (1.179--1.703)     1.394 (1.209--1.607)
                          BB vs. AA        Asian          6       0.201        **1.706E-05^\*\*^**   1.540 (1.185--2.003)     1.572 (1.279--1.931)
                          BB vs. AA        RCC            5       0.772        **7.220E-07^\*\*^**   1.688 (1.372--2.076)     1.687 (1.372--2.075)
                          BB vs. BA+AA     RCC            5       0.780        **1.791E-04^\*\*^**   1.436 (1.189--1.735)     1.435 (1.188--1.733)

*SNP, single nucleotide polymorphism; P~H~, P value of Q test for heterogeneity test; P~A~, P \< 0.05 was considered as statistically significant (bold font mark^\*^) for cancer type subgroup analysis. And multiple testing P value according to Bonferroni correction \[P \< 0.05 / (12 polymorphisms × 5 models)\] was considered as statistically significant (bold font mark^\*\*^); PCa, prostate cancer; RCC, renal cell carcinoma; BCa, bladder cancer; HB, hospital based; PB, population based; HWE, Hardy Weinberg equilibrium. Heterogeneity was considered significant when the P-value \< 0.1. A fixed effects model (Der-Simonian Laird) was used if there was no significant heterogeneity; otherwise, a random effects model (Der-Simonian Laird) was used*.

eNOS-rs2070744
--------------

The pooled results of five included studies had shown eNOS-rs2070744 polymorphism conferred a significantly higher overall risk to urogenital carcinomas in allele, homozygote and recessive models (B vs. A: *OR* = 1.379, 95%CI = 1.187--1.602, *P*~*A*~ = 2.566E-05; BB vs. AA: *OR* = 2.097, 95%CI = 1.495--2.942, *P*~*A*~ = 1.814E-05 and BB vs. BA + AA: *OR* = 1.898, 95%CI = 1.390--2.591, *P*~*A*~ = 5.468E-05), respectively. In the stratification analysis by source of control, an increased risk of urogenital neoplasms was also identified for P-B groups in allele, homozygote, and recessive models (B vs. A: *OR* = 1.437, 95%CI = 1.167--1.768, *P*~*A*~ = 6.260E-04; BB vs. AA: *OR* = 2.481, 95%CI = 1.532--4.019, *P*~*A*~ = 2.220E-04 and BB vs. BA + AA: *OR* = 2.352, 95%CI = 1.501--3.687, *P*~*A*~ = 1.915E-04). Moreover, when the stratification analysis conducted by cancer type (*P*~*A*~ value \< 0.05, without Bonferroni correction), we also identified an increased risk of BCa in allelic, dominant, homozygote and recessive models (B vs. A: *OR* = 1.388, 95%CI = 1.090--1.768, *P*~*A*~ = 7.782E-03; BA+BB vs. AA: *OR* = 1.402, 95%CI = 1.017--1.932, *P*~*A*~ = 3.913E-02; BB vs. AA: *OR* = 2.298, 95%CI = 1.266--4.172, *P*~*A*~ = 6.251E-03 and BB vs. BA + AA: *OR* = 2.006, 95%CI = 1.145--3.516, *P*~*A*~ = 1.503E-02). An increased risk of PCa in allelic, dominant, homozygote, and recessive models (B vs. A: *OR* = 1.373, 95%CI = 1.135--1.662, *P*~*A*~ = 1.113E-03; BA+BB vs. AA: *OR* = 1.375, 95%CI = 1.045--1.808, *P*~*A*~ = 2.278E-02; BB vs. AA: *OR* = 2.000, 95%CI = 1.325--3.018, *P*~*A*~ = 9.759E-04 and BB vs. BA + AA: *OR* = 1.848, 95%CI = 1.271--2.687, *P*~*A*~ = 1.300E-03).

eNOS-intron 4a/b VNTR
---------------------

For eNOS-Intron 4a/b VNTR polymorphism, a total of six eligible case-control studies were included. The final analysis has shown that eNOS-Intron 4a/b VNTR polymorphism was related to an increased risk of urogenital neoplasms in recessive model (BB vs. BA + AA: *OR* = 2.725, 95%CI = 1.608--4.619, *P*~A~ = 1.970E-04). Subgroups analysis (*P*~*A*~ value without Bonferroni correction) identified an increased risk of BCa in homozygote models (BB vs. AA: *OR* = 2.661, 95%CI = 1.004--7.050, *P*~*A*~ = 4.899E-02).

eNOS-rs1799983
--------------

Overall, there was no significant association between eNOS-rs1799983 polymorphism and the risk of urogenital neoplasms. However, subgroups analysis by cancer type revealed an increased risk of BCa in allelic and heterozygote models (B vs. A: *OR* = 1.324, 95%CI = 1.067--1.642, *P*~A~ = 1.078E-02; BB vs. AA: *OR* = 1.887, 95%CI = 1.103--3.230, *P*~A~ = 2.056E-02) (*P*~*A*~ value without Bonferroni correction).

HIF1a-rs11549467
----------------

Overall, there was no significant association between HIF1a-rs11549467 polymorphism and the risk of urogenital neoplasms. Subgroups analysis by cancer type revealed an increased risk of PCa in allelic and heterozygote models (B vs. A: *OR* = 1.465, 95%CI = 1.010--2.124, *P*~A~ = 4.413E-02) (*P*~*A*~ value without Bonferroni correction).

HRAS-rs12628
------------

No significant association was uncovered for the association between HRAS-rs12628 polymorphism and urogenital carcinomas risk. However, when conducting the stratification analysis by HWE status, we identified an increased risk of urogenital carcinomas (all are BCa studies) in dominant and homozygote model for HWE (Y) groups (BB + BA vs. AA: *OR* = 2.211, 95%CI = 1.517--3.222, *P*~*A*~ = 3.647E-05; BB vs. AA: *OR* = 4.174, 95%CI = 1.851--9.412, *P*~*A*~ = 5.725E-04). Moreover, in the stratification analysis by source of control, an increased risk of urogenital carcinomas for H-B groups was also found (BB vs. BA+AA: *OR* = 2.396, 95%CI = 1.458--3.938, *P*~*A*~ = 5.642E-04).

VEGF-rs2010963
--------------

Overall, there was no significant association between eNOS-rs1799983 polymorphism and the risk of urogenital neoplasms. Nevertheless, subgroups analysis by cancer type revealed an increased risk of RCC in heterozygote, dominant, and homozygote models (BA vs. AA: *OR* = 1.168, 95%CI = 1.027--1.328, *P*~*A*~ = 1.762E-02; BA+BB vs. AA: *OR* = 1.181, 95%CI = 1.047--1.333, *P*~*A*~ = 6.790E-03; BB vs. AA: *OR* = 1.196, 95%CI = 1.010--1.416, *P*~*A*~ = 3.784E-02) (*P*~*A*~ value without Bonferroni correction).

VEGF-rs3025039
--------------

No significant association was found between VEGF-rs3025039 polymorphism and the risk of urogenital carcinomas. Nevertheless, subgroup analysis by ethnicity showed an increased risk of urogenital carcinomas in allelic and homozygote model for Asian population (B vs. A: *OR* = 1.180, 95%CI = 1.076--1.294, *P*~*A*~ = 4.545E-04; BB vs. AA: *OR* = 1.401, 95%CI = 1.152--1.705, *P*~*A*~ = 7.532E-04). Moreover, in the stratification analysis by source of control, an increased risk of urogenital carcinomas for H-B groups was also found (BB vs. AA: *OR* = 1.405, 95%CI = 1.163--1.699, *P*~*A*~ = 4.316E-04). Subgroups analysis by cancer type (*P*~*A*~ value without Bonferroni correction) revealed an increased risk of RCC in allelic, dominant, homozygote, and recessive models (B vs. A: *OR* = 1.198, 95%CI = 1.074--1.336, *P*~*A*~ = 1.199E-03; BA+BB vs. AA: *OR* = 1.205, 95%CI = 1.046--1.389, *P*~*A*~ = 9.705E-03; BB vs. AA: *OR* = 1.383, 95%CI = 1.111--1.721, *P*~*A*~ = 3.699E-03; BB vs. BA+AA: *OR* = 1.278, 95%CI = 1.041--1.570, *P*~*A*~ = 1.930E-02).

VEGF-rs699947
-------------

Overall, there was no significant association between VEGF-rs699947 polymorphism and the risk of urogenital neoplasms. Nonetheless, an increased risk of urogenital carcinomas for Asian populations in allelic, heterozygote, dominant, and homozygote models were found in the stratification analysis by ethnicity (B vs. A: *OR* = 1.277, 95%CI = 1.158--1.408, *P*~*A*~ = 9.201E-07; BA vs. AA: *OR* = 1.352, 95%CI = 1.166--1.568, *P*~*A*~ = 6.730E-05; BB + BA vs. AA: *OR* = 1.410, 95%CI = 1.226--1.620, *P*~*A*~ = 1.339E-06 and BB vs. AA: *OR* = 1.572, 95%CI = 1.279--1.931, *P*~*A*~ = 1.706E-05). Moreover, when the stratification analysis conducted by cancer type, we also identified an increased risk of RCC in allelic, heterozygote, dominant, homozygote, and recessive models (B vs. A: *OR* = 1.312, 95%CI = 1.186--1.450, *P*~*A*~ = 1.311E-07; BA vs. AA: *OR* = 1.306, 95%CI = 1.122--1.521, *P*~*A*~ = 5.669E-04; BB + BA vs. AA: *OR* = 1.394, 95%CI = 1.209--1.607, *P*~*A*~ = 4.602E-06; BB vs. AA: *OR* = 1.687, 95%CI = 1.372--2.075, *P*~*A*~ = 7.220E-07 and BB vs. BA + AA: *OR* = 1.435, 95%CI = 1.188--1.733, *P*~*A*~ = 1.791E-04).

VEGF-rs10434, VEGF-rs1570360, VEGF-rs833061, and HIF1a-rs11549465
-----------------------------------------------------------------

There was no significant association between VEGF-rs10434, VEGF-rs1570360, VEGF-rs2010963, VEGF-rs833061, and HIF1α-rs11549465 polymorphisms and the risk of urogenital carcinomas. Furthermore, in the subgroup analysis by ethnicity, source of controls, cancer type or HWE status, similar results were also obtained.

Sensitivity analysis and publication bias
-----------------------------------------

In order to assess the stability of current meta-analysis result, sensitivity analysis was performed. The influence of the individual dataset on the pooled ORs was investigated after sequentially excluding each single case-control study. The study material alteration did not change the corresponding pooled ORs for all 12 polymorphisms (Supplementary Figure [1](#SM1){ref-type="supplementary-material"} and Supplementary Table [4](#SM6){ref-type="supplementary-material"}). Furthermore, Begg\'s funnel plot and Egger\'s regression test were performed to evaluate the publication bias (Begg and Mazumdar, [@B4]; Egger et al., [@B16]). As for these 12 polymorphisms, no evidence of publication bias was identified by viewing the shape of Begg\'s funnel plot, which was further validated by Egger\'s regression test (Supplementary Figure [2](#SM2){ref-type="supplementary-material"} and Supplementary Table [5](#SM7){ref-type="supplementary-material"}).

LD analyses across populations
------------------------------

To better understand the quantitative synthesis, we performed LD analysis to test for the existence of bins in the region comprising these polymorphisms of each angiogenesis related genes (VEGF-rs10434, VEGF-rs1570360, VEGF-rs2010963, VEGF-rs3025039, VEGF-rs699947, VEGF-rs833061, HIF1α-rs11549465, HIF1α-rs11549467, eNOS-rs1799983, and eNOS-rs2070744), respectively. LD plots for polymorphisms in each gene were presented in Figure [2](#F2){ref-type="fig"} and Supplementary Table [6](#SM8){ref-type="supplementary-material"}. Although we have uncovered significant LD for several polymorphisms in separate genes, such as VEGF, they were not statistically associated with urological neoplasms\' risk in current work. As for the two significant polymorphisms (eNOS-Intron 4a/b VNTR and eNOS-rs2070744), LD analysis cannot be performed because eNOS-Intron 4a/b VNTR polymorphism was mismatched.

![Linkage disequilibrium analyses for VEGF, eNOS, and HIF1α polymorphisms in populations from 1,000 genomes. The number of each cell represents *r*^2^ and white color cells shows no LD between polymorphisms. Population descriptors: JPT, Japanese in Tokyo, Japan; YRI, Yoruba in Ibadan, Nigeria; CEU, Utah residents with Northern and Western European ancestry from the CEPH collection; CHB, Han Chinese in Beijing, China.](fphys-09-00715-g0002){#F2}

Discussion {#s4}
==========

Angiogenesis is well-recognized as a key element for sustained tumor growth and a critical factor for tumor metastasis (McConkey et al., [@B42]; De Palma et al., [@B11]). Our previous studies also demonstrated upregulation of angiogenesis genes, e.g., VEGF played vital roles in bladder cancer progression (Zu et al., [@B80]; Lei et al., [@B32]; Zhou et al., [@B78]; Chen et al., [@B9]; Long et al., [@B37]). Other researchers also suggested that polymorphisms in angiogenesis pathway genes might be an important risk factors for the initiation and progression of urogenital neoplasms (Jacobs et al., [@B26]; Jaiswal et al., [@B28]; Orlandi et al., [@B49]; Dornbusch et al., [@B13]; Gong et al., [@B21]).

Some investigators have conducted case-control studies to evaluate the association between polymorphisms in angiogenesis related genes and the risk of urological tumors (Foley et al., [@B17]; Henríquez-Hernández et al., [@B23]; Li et al., [@B35]). However, most of prior studies addressed on limited polymorphisms in single angiogenesis related gene while neglected potential multiple gene\'s influence on urological carcinogenesis. Xian et al. found VEGF-rs3025039 genetic variant was associated with increased risk of RCC (Xian et al., [@B73]), but another study revealed no association (Abe et al., [@B1]). Li P et al. reported HIF1α-rs11549467 rather than HIF1α-rs11549465 polymorphism increased prostate cancer susceptibility (Li et al., [@B35]). Other studies failed to detect any association between these two polymorphisms and the risk of urinary cancers (Clifford et al., [@B10]; Morris et al., [@B44]). One study showed the eNOS-rs1799983 was associated with increased prostate cancer risk (Medeiros et al., [@B43]), while another study data suggested no association (Brankovic et al., [@B5]). HRAS-rs12628 polymorphism could mediate urinary bladder cancer development and predict tumors advancing (Amasyali et al., [@B3]), but another study showed no significant correlation (Sanyal et al., [@B61]). In the current study, we presented a comprehensive meta-analysis for 12 polymorphisms in four VEGF/hypoxia/angiogenesis pathway genes (VEGF, HIF1α, eNOS, and HRAS) including 96 case-control studies to examine the precise associations between these polymorphisms and risk of urogenital neoplasms.

Previous studies revealed that eNOS could modulate cancer-related events, such as VEGF-induced angiogenesis, invasion, and metastasis (Jadeski et al., [@B27]; Duda et al., [@B14]). The eNOS-rs2070744 polymorphism is a point mutation of thymine to cytosine (T\>C) at −786 nucleotide in the 5′-flanking region of the eNOS gene (Nakayama et al., [@B46]). This mutation position in eNOS promoter region can alter gene activity and serum NO level, indicating the CC homozygote carriers may have an increased risk of cancer (Zhang et al., [@B75]). Present meta-analysis indicated that eNOS-rs2070744 polymorphism conferred a significantly increased overall risk to urogenital neoplasms. This is consistent with several previously published studies (Ryk et al., [@B57]; Brankovic et al., [@B5]; Safarinejad et al., [@B59]; Polat et al., [@B52]; Diler and Oden, [@B12]). The eNOS-Intron 4a/b VNTR polymorphism is a variable number of tandem repeats (27 nt) in intron 4 participating in basal plasma NO generation (Wang et al., [@B71]). Our final analysis results suggested that this polymorphism was related to an increased risk of urogenital neoplasms in recessive model. However, 6 case-control studies for eNOS-Intron 4a/b VNTR polymorphism enrolled in our study, there were two studies showed no significant relationship between this polymorphism and urogenital neoplasms (Sanli et al., [@B60]; Diler and Oden, [@B12]).

Although no significant association was uncovered between the association between VEGF-rs699947 polymorphism and the risk of urogenital neoplasms. In the subgroup analysis by ethnicity, we found an increased risk of urogenital neoplasms in Asian populations. Moreover, when the stratification analysis conducted by cancer type, we also identified an increased risk for RCC subtype. Similar results were found between VEGF-rs3025039 polymorphism and risk of urogenital neoplasms. Nevertheless, in the subgroup analysis of ethnicity, we observed an increased risk of urogenital neoplasms in allelic model for Asian populations. Moreover, in stratification analysis by source of control, an increased risk of urogenital neoplasms for H-B groups was also uncovered. Deviations in HWE status were influenced by methodological problems, such as the genotyping errors, the population stratification or selection bias, et al. Thus, we have conducted subgroup analyses by HWE status. For the HRAS-rs12628 polymorphism, we identified an increased risk of urogenital neoplasms in the dominant model for HWE (Y) groups.

While for VEGF (rs3025039, rs10434, rs1570360, rs2010963, and rs833061), HIF1α (rs11549465 and rs11549467), HRAS-rs12628 and eNOS-rs1799983 polymorphisms, our meta-analysis indicated there were no significant associations between them and urogenital neoplasms susceptibility even in subgroup analysis by ethnicity, HWE status, source of controls and cancer type (multiple testing *P*-value according to Bonferroni correction \[*P* \< 0.05/(12 polymorphisms × 5 models)\] was considered as statistically significant). However, we also prefer to identify markers for specific tumors (eg. RCC, BCa, and PCa). For these SNPs, *P*~*A*~ \< 0.05 was considered as statistically significant for cancer type subgroup analysis. Results suggested VEGF-rs699947, VEGF-rs3025039, and VEGF-rs2010963 polymorphisms may be a potential risk factor for RCC. And eNOS-rs2070744, eNOS-Intron 4a/b VNTR, eNOS-rs1799983, and HRAS-rs12628 polymorphisms may be a risk factor for BCa. In addition, eNOS-rs2070744 and HIF1a-rs11549467 polymorphisms may be a risk factor for PCa. Accordingly, these subgroups results suggested these SNPs might be used as potential diagnostic markers for RCC, BCa, and PCa, respectively. There are several important advantages for the current meta-analysis. First and foremost, we implemented a comprehensive database search to identify all eligible studies in the VEGF/hypoxia/angiogenesis pathway, making our meta-analysis more substantial and persuasive. Second, all included studies were assessed by Newcastle Ottawa Scale, aiming to exclude low quality studies and elevate the overall quality. Third, various subgroup analyses based on ethnicity, HWE status, source of controls and cancer type were performed, trying to further stratify the sources of heterogeneity. Fourth, in order to making our analysis more accurate, the recognized formula was performed to adjust the results. In addition, sensitivity analysis was applied to confirm the stability of included studies, and Begg\'s funnel plot and Egger\'s test was utilized to analyze publication bias.

However, several limitations should also be noted in our present meta-analysis. First, for several polymorphisms, particularly when the case number in the studies was small, it may result in an insufficient power for identifying weak association between these polymorphisms and urogenital neoplasms susceptibility. Second, we currently didn\'t validate these polymorphisms with related clinical consequences. In the follow-up study, we will focus on the functional aspects of how these polymorphisms affect genes expression and ultimately associate with tumorigenesis. Third, all of the included studies were restricted in English, exclusion of other languages studies may increase the publication bias. Fourth, we didn\'t consider several potential confounding factors in this study, such as the age, gender, smoking habit, drinking status, and environmental factors, etc. This limited us further study the genetic and environmental interaction model. Therefore, the current result should be cautious interpreted.

In summary, in conjunction with other studies, current meta-analysis results suggest that eNOS-rs2070744 and eNOS-Intron 4a/b VNTR polymorphisms are associated with elevated risk of urogenital carcinomas. In addition, VEGF-rs699947 polymorphism was also identified as an risk factor for renal carcinoma. Further well-designed case-control studies with large population size are warranted to strengthen our findings.
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